Twin Peaks Wealth Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-367
Closed -$46.9K 2247
2026
Q1
$46.9K Buy
+367
New +$45.8K 0.01% 450
2025
Q3
Sell
-367
Closed -$31.9K 2174
2025
Q2
$31.9K Buy
+367
New +$29.3K 0.01% 455

Other funds holding XBI

Twin Peaks Wealth Advisors's XBI Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, closing a stake of 367 shares — an estimated $46.9K sold.

Twin Peaks Wealth Advisors first reported a position in XBI in Q2 2025 and held it in 2 quarters. The position peaked at $46.9K in Q1 2026. 934 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 367 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $46.9K.
  • Twin Peaks Wealth Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's State Street SPDR S&P Biotech ETF position peaked at $46.9K in Q1 2026.
  • 934 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.